[Earnings Flash] JCR Pharmaceuticals Co., Ltd., interim ordinary loss of ¥3,798 million (IFIS Stock Forecast)

JCR Pharmaceuticals announced its interim results for the fiscal year ending March 2027. Ordinary profit/loss was -¥3,798 million, and the full-year forecast is reported to remain unchanged at ¥500 million.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

JCR Pharmaceuticals announced its interim results for the fiscal year ending March 2027, reporting ordinary profit/loss of -¥3,798 million.

The full-year ordinary profit/loss forecast announced on the same day remains unchanged from the previous forecast at ¥500 million. An approximately 57.1% year-on-year decline in earnings is expected. The figure is also reported to be 2.6% below the IFIS consensus.

At a glance

TimingOrdinary profit/loss for the interim period of the fiscal year ending March 2027 was -¥3,798 million

AmountFull-year ordinary profit/loss forecast held at ¥500 million

NatureExpected to come in 2.6% below the IFIS consensus

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

2/ 2 agree

All of them report the same thing.

google.comNews

AgreesOpen

finance.yahoo.co.jpNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.